Strengthening the Evidence: Similar Rates of Neural Tube Defects Among Deliveries Regardless of Maternal HIV Status and Dolutegravir Exposure in Hospital Birth Surveillance in Eswatini
Authors:
Open Access
- 18 August 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (9) , ofad441
Abstract
Birth defect surveillance in Eswatini in 2020–2021 identified 0.80% defects (197/24 599 live and stillborn infants). Neural tube defect (NTD) prevalence was 0.08%, 0.08%, and 0.15% for 4902 women on dolutegravir preconception, 17 285 HIV-negative women, and 1320 women on efavirenz preconception, respectively, more definitively refuting the dolutegravir preconception NTD safety signal.Keywords
Funding Information
- ViiV Healthcare
This publication has 6 references indexed in Scilit:
- Implementation and outcomes of dolutegravir-based first-line antiretroviral therapy for people with HIV in South Africa: a retrospective cohort studyThe Lancet HIV, 2023
- Neural tube defects: a review of global prevalence, causes, and primary preventionChild's Nervous System, 2023
- Transitioning women to first-line preferred TLD regimen is lagging in Sub-Saharan AfricaClinical Infectious Diseases, 2022
- Neural-Tube Defects and Antiretroviral Treatment Regimens in BotswanaNew England Journal of Medicine, 2019
- Neural-Tube Defects with Dolutegravir Treatment from the Time of ConceptionNew England Journal of Medicine, 2018
- Teratogenicity risk of antiretroviral therapy in pregnancyCurrent HIV/AIDS Reports, 2007